Paradromics and University of Michigan Complete First Connexus® BCI Implantation for the FDA-Approved Connect-One Clinical Study (opens original article in a new tab)

Paradromics and the University of Michigan completed the first Connexus® brain-computer interface implantation as part of an FDA-approved clinical study to restore communication for individuals with severe motor impairments.

• Paradromics and University of Michigan completed the first Connexus® BCI implantation for the FDA-approved Connect-One Clinical Study.
• The Connexus® BCI is designed to restore speech and enable computer control for people with severe motor impairment by recording and translating neural signals.
• The study will follow the first participant for six years to evaluate the long-term safety and effectiveness of the BCI technology.